{"filings":[{"id":746517,"accession_number":"0001193125-26-248246","cik":1746466,"company_name":"Equillium, Inc.","ticker":"EQ","form_type":"8-K","filed_at":"2026-05-29T20:05:29+00:00","items":["5.07","9.01"],"status":"ready","headline":"Equillium stockholders approve reverse stock split and authorized share increase at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split approved at ratio of 1-for-2 to 1-for-20, with timing and ratio at Board's discretion.","Authorized common shares increased from 200M to 400M; 42.7M for, 11.6M against.","Directors Charles McDermott and Bruce Steel elected to Class II; board reduced from 7 to 6 as Peter Colabuono not renominated.","Ratification of Crowe LLP as independent auditor for FY 2026: 54.3M for, 5,234 against.","Shareholder turnout 85.86% (54.3M of 63.2M shares)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":189047407.80608368,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":68015,"accession_number":"0001193125-26-221595","cik":1746466,"company_name":"Equillium, Inc.","ticker":"EQ","form_type":"8-K","filed_at":"2026-05-13T20:05:19+00:00","items":["2.02","9.01"],"status":"ready","headline":"Equillium Q1 net loss narrows to $5.3M; EQ504 Phase 1 on track for mid-2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 net loss of $5.3M ($0.06/sh) vs. $8.7M ($0.24/sh) in Q1 2025; R&D spending down to $3.0M.","Cash and equivalents $61.3M as of March 31, 2026; funded into 2029; includes $35M March private placement.","Phase 1 proof-of-mechanism study of EQ504 (AhR modulator) on track for mid-2026, data ~6 months later.","Appointed Snehal Naik, Ph.D., as Chief Development Officer; she brings >15 years immunology experience.","Evaluating further advancement of EQ302 (IL-15/IL-21 inhibitor) for GI indications."],"consensus_eps_estimate":-0.0446,"consensus_eps_actual":-0.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":189047407.80608368,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108013,"accession_number":"0001193125-26-124107","cik":1746466,"company_name":"Equillium, Inc.","ticker":"EQ","form_type":"8-K","filed_at":"2026-03-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Equillium Q4 2025 revenue $0, net loss $3.8M; cash runway into 2029 after $35M financing","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 revenue $0 (vs $4.4M Q4 2024); FY2025 revenue $0 (vs $41.1M FY2024 from Ono deal).","Net loss Q4 2025 $3.8M ($0.04/share); full year 2025 loss $22.4M ($0.39/share), up from $8.1M loss in 2024.","Cash & equivalents $30.3M at Dec 31, 2025; plus $35M private placement from RA Capital in March 2026.","EQ504 Phase 1 proof-of-mechanism study expected to start mid-2026 with data ~6 months later.","Company believes cash runway funds planned operations into 2029."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":189047407.80608368,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108012,"accession_number":"0001193125-26-105083","cik":1746466,"company_name":"Equillium, Inc.","ticker":"EQ","form_type":"8-K","filed_at":"2026-03-13T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Equillium raises ~$35M in private placement with RA Capital to fund EQ504","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 1,179,508 shares at $1.854/share and pre-funded warrant for up to 17,698,593 shares at $0.0001 exercise price.","Gross proceeds of approximately $35.0 million from RA Capital Healthcare Fund, L.P.","Closing expected on or about March 13, 2026, subject to customary conditions.","Net proceeds to fund development of EQ504 and for working capital and general corporate purposes.","Registration rights agreement to be filed with SEC within 30 days of closing; cash penalties for registration failures."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":189047407.80608368,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124423,"accession_number":"0001193125-25-280173","cik":1746466,"company_name":"Equillium, Inc.","ticker":"EQ","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Equillium reports Q3 net loss of $4.2M; announces $50M financing and EQ504 Phase 1 plan for mid-2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 2025 revenue $0 vs $12.2M in prior year; net loss $4.2M ($0.06 per share) vs $7,000 loss in Q3 2024.","Closed private placement of up to $50M; initial $30M tranche funded by ADAR1, Janus Henderson, Adage, Coastlands, Woodline.","Cash and investments $33.1M at Sep 30, 2025 vs $22.6M at Dec 31, 2024; expected runway through 2027.","EQ504 (AhR modulator) for ulcerative colitis Phase 1 study expected to initiate mid-2026."],"consensus_eps_estimate":-0.1493,"consensus_eps_actual":-0.41,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":189047407.80608368,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124421,"accession_number":"0001193125-25-249953","cik":1746466,"company_name":"Equillium, Inc.","ticker":"EQ","form_type":"8-K/A","filed_at":"2025-10-24T23:59:59+00:00","items":["4.01"],"status":"ready","headline":"Equillium confirms Crowe LLP as auditor for FY2025, effective Oct 21, 2025","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Engagement letter with Crowe LLP executed Oct 21, 2025; client acceptance procedures completed same day.","Appointment covers fiscal year ending Dec 31, 2025, subject to standard terms.","No prior consultations with Crowe regarding accounting principles, disagreements, or reportable events.","Audit committee previously approved Crowe selection; amendment provides final details."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":189047407.80608368,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124422,"accession_number":"0001193125-25-231860","cik":1746466,"company_name":"Equillium, Inc.","ticker":"EQ","form_type":"8-K","filed_at":"2025-10-06T23:59:59+00:00","items":["4.01","5.02","8.01","9.01"],"status":"ready","headline":"Equillium ends Biocon itolizumab deal, dismisses KPMG, two directors resign","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Terminated collaboration with Biocon; all itolizumab licenses reverted. Technical service fee of $363k set-off against amounts owed.","Dismissed KPMG as auditor (effective Sep 30); engaged Crowe LLP pending finalization. KPMG reports had going-concern qualification.","Directors Stephen Connelly (Ph.D.) and Bala Manian (Ph.D.) resigned effective Oct 1; board reduced from 9 to 7.","Appointed Dr. Connelly as President (remains CSO); no comp change. Daniel Bradbury shifted from Executive Chairman to Chairman."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":189047407.80608368,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141093,"accession_number":"0001193125-25-209068","cik":1746466,"company_name":"Equillium, Inc.","ticker":"EQ","form_type":"8-K","filed_at":"2025-09-19T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Equillium ups ATM facility to $75M from $21.95M; prior sales $0.96M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed prospectus supplement to increase aggregate offering price of common stock under existing Sales Agreement to $75M.","Sales Agreement with LifeSci Capital LLC, dated Oct 2023, amended Aug 2025, governs the at-the-market offering.","Previously sold 1,719,485 shares for aggregate gross proceeds of approximately $0.96M.","New supplement amends prior ATM prospectus dated Jan 2023, as supplemented Oct 2023 and Feb 2024.","No specific use of proceeds stated in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":189047407.80608368,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141092,"accession_number":"0000950170-25-113023","cik":1746466,"company_name":"Equillium, Inc.","ticker":"EQ","form_type":"8-K","filed_at":"2025-09-04T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Equillium regains Nasdaq minimum bid price compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Equillium on Aug 29, 2025 that it has regained compliance with the $1.00 minimum bid price rule.","Compliance required closing bid price of $1.00+ for 10 consecutive business days; achieved on Aug 28, 2025.","Equillium had previously received a non-compliance notice on Dec 13, 2024 and an extension on June 12, 2025.","The company's common stock (Nasdaq: EQ) is now compliant for continued listing on The Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":189047407.80608368,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141091,"accession_number":"0001193125-25-177510","cik":1746466,"company_name":"Equillium, Inc.","ticker":"EQ","form_type":"8-K","filed_at":"2025-08-11T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Equillium raises $30M in private placement; cash runway through 2027","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Initial closing of 21.8M shares at $0.57/sh and pre-funded warrants for 30.8M shares, gross proceeds $30M.","Potential milestone closing of up to $20M upon IND clearance or first patient dosing for EQ504 and stock price threshold.","Net proceeds expected to extend cash runway through 2027, prioritizing EQ504 development.","Company has not initiated cryptocurrency treasury reserve strategy as previously announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":189047407.80608368,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141090,"accession_number":"0001193125-25-172207","cik":1746466,"company_name":"Equillium, Inc.","ticker":"EQ","form_type":"8-K","filed_at":"2025-08-04T23:59:59+00:00","items":["1.01","2.02","7.01","8.01","9.01"],"status":"ready","headline":"Equillium adopts crypto treasury strategy; cash $11.5M, runway into Q4 2025; going concern doubt","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash and cash equivalents $11.5M as of June 30, 2025; expects to fund operations into Q4 2025.","Amended investment policy to allow cryptocurrency purchases; no crypto purchased yet, plans updates in Q3 2025.","Pipeline paused: preparing EQ504 for clinical development subject to raising capital; development activities paused.","Replaced ATM sales agent from Jefferies to LifeSci Capital; $21.95M available under ATM facility.","Going concern doubt: substantial doubt about ability to continue; need additional capital immediately."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":189047407.80608368,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158897,"accession_number":"0000950170-25-086155","cik":1746466,"company_name":"Equillium, Inc.","ticker":"EQ","form_type":"8-K","filed_at":"2025-06-13T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Equillium receives Nasdaq extension to Dec 8, 2025 for bid price compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq granted Equillium (EQ) until Dec 8, 2025 to regain minimum $1.00 bid price compliance.","Original 180-day compliance period ended June 11, 2025; extension provides additional 180 calendar days.","If not compliant by Dec 8, 2025, staff will issue delisting notice; company may appeal to hearings panel.","Company will monitor bid price and consider reverse stock split or other options to regain compliance.","Stock continues trading on Nasdaq Capital Market under symbol EQ; no immediate delisting effect."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":189047407.80608368,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158896,"accession_number":"0001193125-25-125153","cik":1746466,"company_name":"Equillium, Inc.","ticker":"EQ","form_type":"8-K","filed_at":"2025-05-22T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Equillium stockholders approve reverse stock split and equity plan amendment","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders authorized reverse stock split at ratio 1:2 to 1:20, with board discretion on timing and ratio.","Amendment to 2018 Equity Incentive Plan approved, increasing authorized shares by 1,781,000.","Three Class I directors re-elected: Stephen Connelly, Bala S. Manian, Barbara Troupin.","KPMG ratified as independent auditor for fiscal year 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":189047407.80608368,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158895,"accession_number":"0001193125-25-092435","cik":1746466,"company_name":"Equillium, Inc.","ticker":"EQ","form_type":"8-K","filed_at":"2025-04-24T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Equillium announces FDA declined Breakthrough Therapy and Accelerated Approval for itolizumab in aGVHD","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA declined Breakthrough Therapy designation and Accelerated Approval for itolizumab in aGVHD based on EQUATOR study data.","FDA focused on Day 29 outcomes; itolizumab did not show improvement by Day 29 despite favorable safety and longer-term data.","Company plans to accelerate closure of EQUATOR study and evaluate options to advance or partner itolizumab.","Cash and equivalents $14.5M as of March 31, 2025; expected to fund operations into Q3 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":189047407.80608368,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177301,"accession_number":"0000950170-25-045723","cik":1746466,"company_name":"Equillium, Inc.","ticker":"EQ","form_type":"8-K","filed_at":"2025-03-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Equillium Reports Q4 and Full Year 2024 Financial Results and Provides Clinical Updates","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Phase 3 EQUATOR study in aGVHD: primary endpoint not met, but statistically significant longer-term outcomes (CR at Day 99, duration of CR, failure-free survival).","Full year 2024 revenue $41.1M, up from $36.1M in 2023; net loss $8.1M ($0.23/share) vs $13.3M ($0.38/share) in 2023.","Cash and investments $22.6M as of Dec 31, 2024; expected to fund operations into Q3 2025.","FDA meeting requested for Accelerated Approval of itolizumab in aGVHD; feedback expected May 2025.","Positive Phase 2 data for itolizumab in ulcerative colitis: clinical remission rate 23.3% vs 10.0% placebo at 12 weeks."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":189047407.80608368,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177300,"accession_number":"0001193125-25-021348","cik":1746466,"company_name":"Equillium, Inc.","ticker":"EQ","form_type":"8-K","filed_at":"2025-02-06T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Equillium reports itolizumab Phase 2 UC topline: 23.3% clinical remission vs 10% placebo","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Primary endpoint: 23.3% clinical remission at week 12 for itolizumab vs 20.0% adalimumab, 10.0% placebo.","Secondary: 63.3% clinical response (itolizumab) vs 60.0% adalimumab, 46.7% placebo; endoscopic remission 16.7% each itolizumab/adalimumab vs 6.7% placebo.","Baseline imbalance: 23% of itolizumab arm had severe disease (Mayo=11) vs 0% placebo/adalimumab; 66% left-sided colitis vs 30%/43%.","Itolizumab was generally well tolerated with no new safety signal; 90 patients randomized 1:1:1 in India."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":189047407.80608368,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194061,"accession_number":"0001193125-24-278465","cik":1746466,"company_name":"Equillium, Inc.","ticker":"EQ","form_type":"8-K","filed_at":"2024-12-13T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Equillium receives Nasdaq minimum bid price non-compliance notice; cure period until June 11, 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Equillium on Dec 13, 2024 that common stock bid price was below $1.00 for 30 consecutive business days.","Company has 180 calendar days, until June 11, 2025, to regain compliance with the Minimum Bid Price Requirement.","To cure, minimum bid must close at $1.00 or higher for at least ten consecutive business days during the grace period.","If not cured by June 2025, Equillium may qualify for a second 180-day compliance period if it meets other listing standards.","Equillium intends to monitor bid price and is considering options such as a reverse stock split to regain compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":189047407.80608368,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194060,"accession_number":"0001193125-24-277043","cik":1746466,"company_name":"Equillium, Inc.","ticker":"EQ","form_type":"8-K","filed_at":"2024-12-12T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Equillium director Yu Xu resigns; Peter Colabuono appointed to board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Yu (Katherine) Xu, Ph.D., resigned from Equillium board and audit committee effective Dec 10, 2024; no disagreement cited.","Peter Colabuono appointed Class II director, term expiring at 2026 annual meeting, filling Xu's vacancy.","Colabuono receives $42,000 annual cash retainer, option for 40,000 shares vesting monthly over 3 years.","Further annual automatic option grants of 20,000 shares vesting over 12 months; change-in-control acceleration.","Barbara Troupin, M.D., appointed to audit committee; committee now Demski (chair), Manian, Troupin."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":189047407.80608368,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194059,"accession_number":"0000950170-24-126288","cik":1746466,"company_name":"Equillium, Inc.","ticker":"EQ","form_type":"8-K","filed_at":"2024-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Equillium Q3 revenue $12.2M, net loss near zero; retains itolizumab rights after Ono termination","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenue $12.2M (up 37% YoY) from Ono partnership; net loss ~$7,000 vs $3.7M loss in Q3 2023.","Cash $25.9M; sufficient into Q4 2025 assuming accelerated EQUATOR study, pausing EQ101/EQ302, and cost reductions.","Ono partnership ended after substantial non-dilutive funding; Equillium retains full rights to itolizumab.","Phase 3 EQUATOR aGVHD study enrollment paused; potential topline acceleration to Q1 2025.","Partner Biocon completed Phase 2 ulcerative colitis study; topline data expected Q1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":36703000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":189047407.80608368,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194058,"accession_number":"0001193125-24-248138","cik":1746466,"company_name":"Equillium, Inc.","ticker":"EQ","form_type":"8-K","filed_at":"2024-10-31T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Equillium announces Ono option lapse; pauses EQUATOR enrollment to review acceleration; cash runway into Q4 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Ono's option to acquire itolizumab (EQ001) lapsed; Equillium retains all commercial rights to itolizumab.","EQUATOR Phase 3 study enrollment paused; company plans to accelerate topline data to Q1 2025 with ~150 patients.","Over 150 patients enrolled to date; orphan drug and fast track designations for first-line acute GVHD remain.","Biocon SA completed Phase 2 study of itolizumab in ulcerative colitis; topline data expected Q1 2025.","Company pauses EQ101 and EQ302 activities; cash runway expected into Q4 2025 with accelerated EQUATOR."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":189047407.80608368,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194057,"accession_number":"0001193125-24-247760","cik":1746466,"company_name":"Equillium, Inc.","ticker":"EQ","form_type":"8-K","filed_at":"2024-10-31T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Equillium regains Nasdaq minimum bid price compliance after meeting $1.00 close for 10 days","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on Oct 30, 2024 confirming compliance regained as of Oct 29, 2024.","Previously disclosed non-compliance on July 19, 2024 due to bid price below $1.00.","Stock closed at $1.00 or higher for 10 consecutive business days through Oct 29, 2024.","Nasdaq Capital Market listing maintained without delisting risk."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":189047407.80608368,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210388,"accession_number":"0000950170-24-093884","cik":1746466,"company_name":"Equillium, Inc.","ticker":"EQ","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Equillium Q2 net income $0.5M, revenue $13.9M; Ono itolizumab option decision by Oct 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income $0.5M ($0.01 EPS) vs net loss $3.3M in Q2 2023; revenue $13.9M (all from Ono collaboration), up from $9.1M.","Cash $33.3M, up $1.0M from Q1 2024; expects to fund operations for at least 12 months, adjusting spending if needed.","Ono option to acquire itolizumab rights decision by Oct 2024; if exercised, Equillium receives JPY 5B (~$35M) plus up to $101.4M milestones.","Phase 3 EQUATOR study (aGVHD) IDMC recommends proceed after positive interim review; no safety or futility concerns.","Positive topline data from Phase 1b EQUALISE (lupus nephritis) and Phase 2 EQ101 (alopecia areata); preparing Phase 2b study in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":24542000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":189047407.80608368,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210387,"accession_number":"0001193125-24-182856","cik":1746466,"company_name":"Equillium, Inc.","ticker":"EQ","form_type":"8-K","filed_at":"2024-07-23T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Equillium receives Nasdaq bid price deficiency notice; cure deadline Jan 15, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Received Nasdaq notice on July 19, 2024 for bid price below $1.00 for 30 consecutive business days.","Has 180-day grace period until Jan 15, 2025 to regain compliance by closing at $1.00+ for ten consecutive days.","If not cured, may qualify for additional 180-day period if meeting other initial listing standards.","Company will consider options including a reverse stock split to cure the bid price deficiency.","Common stock continues to trade on Nasdaq Capital Market under symbol 'EQ' with no immediate effect."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":189047407.80608368,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210386,"accession_number":"0001193125-24-180952","cik":1746466,"company_name":"Equillium, Inc.","ticker":"EQ","form_type":"8-K","filed_at":"2024-07-18T23:59:59+00:00","items":["2.02"],"status":"ready","headline":"Equillium estimates cash balance of $33.3M as of June 30, 2024","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Preliminary cash, cash equivalents and short-term investments approximately $33.3 million as of June 30, 2024.","Actual financial statements for Q2 2024 not yet finalized; subject to completion of closing procedures and adjustments.","Preliminary estimate has not been audited, reviewed, or compiled by the independent registered public accounting firm."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":189047407.80608368,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228711,"accession_number":"0001193125-24-153667","cik":1746466,"company_name":"Equillium, Inc.","ticker":"EQ","form_type":"8-K","filed_at":"2024-06-04T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Equillium reports Phase 2 topline data for EQ101 in alopecia areata; 20% of completers achieved SALT ≤20","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Of 25 completers (baseline SALT 35-100), 20% reached SALT ≤20 at week 24; mean SALT improvement 13.5%.","In moderate-to-severe subgroup (n=17), 29% achieved SALT ≤20; mean improvement 18.4% from baseline.","EQ101 well tolerated, no SAEs; 98.9% AEs Grade 1/2; common: URI, headache, fatigue; two Grade 3 events.","Preliminary PD data show reduction of CD132 on CD8 and NK cells, consistent with target engagement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":189047407.80608368,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228710,"accession_number":"0000950170-24-064016","cik":1746466,"company_name":"Equillium, Inc.","ticker":"EQ","form_type":"8-K","filed_at":"2024-05-23T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Equillium stockholders approve reverse stock split amendment at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Approved amendment to certificate of incorporation for reverse stock split at ratio of 1:2 to 1:10, with board discretion on timing and ratio.","Three Class III directors (Bradbury, Demski, Pruzanski) elected; all received substantial votes for with few against.","KPMG LLP ratified as independent auditor for FY2024 with 25,229,542 votes for, 25,305 against.","Advisory say-on-pay approved; stockholders preferred frequency of every three years (11,950,771 votes) over one or two years.","Reverse split authorization gives board flexibility to address Nasdaq minimum bid price or other strategic needs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":189047407.80608368,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228709,"accession_number":"0000950170-24-056890","cik":1746466,"company_name":"Equillium, Inc.","ticker":"EQ","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Equillium Q1 revenue $10.7M, net loss $2.7M; positive lupus data, milestones ahead","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $10.7M, up from $8.9M YoY, all from Ono partnership (development funding and amortization).","Net loss narrowed to $2.7M ($0.08 loss per share) vs $3.9M ($0.11) in Q1 2023.","Cash, cash equivalents and short-term investments $32.3M as of March 31, 2024; runway into 2H 2025.","Positive topline data from Phase 1b EQUALISE study of itolizumab in lupus nephritis announced in early April.","Upcoming: EQ101 Phase 2 alopecia areata topline data Q2 2024; EQUATOR interim review Q3 2024; Ono option exercise decision 2H 2024 (potential ~$32M payment)."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":10689000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":189047407.80608368,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}